Serial Number 97073021
Registration 7202810
700

Registration Progress

Application Filed
Oct 13, 2021
Under Examination
Aug 23, 2022
Approved for Publication
Jun 28, 2022
Published for Opposition
Jun 28, 2022
Registered
Oct 24, 2023

Trademark Image

Basic Information

Serial Number
97073021
Registration Number
7202810
Filing Date
October 13, 2021
Registration Date
October 24, 2023
Published for Opposition
June 28, 2022
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 24, 2023
Registration
Registered
Classes
005 042

Rights Holder

Avidity Biosciences, Inc.

03
Address
10578 Science Drive, Suite 125
San Diego, CA 92121

Ownership History

Avidity Biosciences, Inc.

Original Applicant
03
San Diego, CA

Avidity Biosciences, Inc.

Owner at Publication
03
San Diego, CA

Avidity Biosciences, Inc.

Original Registrant
03
San Diego, CA

Legal Representation

Attorney
Aaron D. Hendelman

USPTO Deadlines

Next Deadline
1546 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-10-24)
Due Date
October 24, 2029
Grace Period Ends
April 24, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

38 events
Date Code Type Description Documents
Oct 24, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Oct 24, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 22, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Sep 21, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Aug 20, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Aug 20, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 10, 2023 IUAF S USE AMENDMENT FILED Loading...
Aug 10, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Aug 8, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 4, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 4, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 4, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 15, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 13, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 13, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 13, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 23, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 28, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 28, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 8, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 11, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 11, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 11, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 22, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 22, 2022 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Apr 22, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 22, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 22, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 21, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 18, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 18, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Feb 18, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 18, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Feb 18, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Nov 4, 2021 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Nov 3, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 16, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Anywhere: Aug 2, 2021
First Use in Commerce: Aug 2, 2021
Class 042
Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
First Use Anywhere: Aug 2, 2021
First Use in Commerce: Aug 2, 2021

Additional Information

Design Mark
The mark consists of 5 parallel wavy lines on top of one another with the first line at the top measuring about half-length of the other 4 lines beneath it.

Classification

International Classes
005 042